Personalized approach brings new hope to pancreatic cancer patients

Headline News

Few early detection tests, undetectable symptoms, limited treatment options and no known biomarkers that can be used to direct therapy. These are among the clinical challenges Canadian research team Enhanced Pancreatic Cancer Profiling for Individualized Care is tackling over the next five years to improve personalized treatments for patients with pancreatic ductal adenocarcinoma PDAC, a disease with just an eight percent five-year survival rate.   

Diabetes drug found not to cause pancreatic cancer


The use of incretin-based drugs is not associated with an increased risk of pancreatic cancer in patients with type 2 diabetes, according to a study published in the latest issue of the British Medical Journal.